Cargando…
The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004127/ https://www.ncbi.nlm.nih.gov/pubmed/36902837 http://dx.doi.org/10.3390/jcm12052050 |
_version_ | 1784904757249310720 |
---|---|
author | Buzzi, Matilde Parisi, Guglielmo Marolo, Paola Gelormini, Francesco Ferrara, Mariantonia Raimondi, Raffaele Allegrini, Davide Rossi, Tommaso Reibaldi, Michele Romano, Mario R. |
author_facet | Buzzi, Matilde Parisi, Guglielmo Marolo, Paola Gelormini, Francesco Ferrara, Mariantonia Raimondi, Raffaele Allegrini, Davide Rossi, Tommaso Reibaldi, Michele Romano, Mario R. |
author_sort | Buzzi, Matilde |
collection | PubMed |
description | The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients with rFTMH after a pars plana vitrectomy (PPV) with internal limiting membrane peeling and gas tamponade. We included 28 eyes from 27 patients with rFTMHs: 12 rFTMHs in highly myopic eyes (axial length greater than 26.5 mm or a refractive error greater than -6D or both); 12 large rFTMHs (minimum hole width > 400 μm); and 4 rFTMHs secondary to the optic disc pit. All patients underwent 25-G PPV with a-PRP, a median time of 3.5 ± 1.8 months after the primary repair. At the six-month follow-up, the overall rFTMH closure rate was 92.9%, distributed as follows: 11 out of 12 eyes (91.7%) in the highly myopic group, 11 out of 12 eyes (91.7%) in the large rFTMH group, and 4 out of 4 eyes (100%) in the optic disc pit group. Median best-corrected visual acuity significantly improved in all groups, in particular from 1.00 (interquartile range: 0.85 to 1.30) to 0.70 (0.40 to 0.85) LogMAR in the highly myopic group (p = 0.016), from 0.90 (0.70 to 1.49) to 0.40 (0.35 to 0.70) LogMAR in the large rFTMH group (p = 0.005), and from 0.90 (0.75 to 1.00) to 0.50 (0.28 to 0.65) LogMAR in the optic disc pit group. No intraoperative or postoperative complications were reported. In conclusion, a-PRP can be an effective adjuvant to PPV in the management of rFTMHs. |
format | Online Article Text |
id | pubmed-10004127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100041272023-03-11 The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes Buzzi, Matilde Parisi, Guglielmo Marolo, Paola Gelormini, Francesco Ferrara, Mariantonia Raimondi, Raffaele Allegrini, Davide Rossi, Tommaso Reibaldi, Michele Romano, Mario R. J Clin Med Article The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients with rFTMH after a pars plana vitrectomy (PPV) with internal limiting membrane peeling and gas tamponade. We included 28 eyes from 27 patients with rFTMHs: 12 rFTMHs in highly myopic eyes (axial length greater than 26.5 mm or a refractive error greater than -6D or both); 12 large rFTMHs (minimum hole width > 400 μm); and 4 rFTMHs secondary to the optic disc pit. All patients underwent 25-G PPV with a-PRP, a median time of 3.5 ± 1.8 months after the primary repair. At the six-month follow-up, the overall rFTMH closure rate was 92.9%, distributed as follows: 11 out of 12 eyes (91.7%) in the highly myopic group, 11 out of 12 eyes (91.7%) in the large rFTMH group, and 4 out of 4 eyes (100%) in the optic disc pit group. Median best-corrected visual acuity significantly improved in all groups, in particular from 1.00 (interquartile range: 0.85 to 1.30) to 0.70 (0.40 to 0.85) LogMAR in the highly myopic group (p = 0.016), from 0.90 (0.70 to 1.49) to 0.40 (0.35 to 0.70) LogMAR in the large rFTMH group (p = 0.005), and from 0.90 (0.75 to 1.00) to 0.50 (0.28 to 0.65) LogMAR in the optic disc pit group. No intraoperative or postoperative complications were reported. In conclusion, a-PRP can be an effective adjuvant to PPV in the management of rFTMHs. MDPI 2023-03-04 /pmc/articles/PMC10004127/ /pubmed/36902837 http://dx.doi.org/10.3390/jcm12052050 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Buzzi, Matilde Parisi, Guglielmo Marolo, Paola Gelormini, Francesco Ferrara, Mariantonia Raimondi, Raffaele Allegrini, Davide Rossi, Tommaso Reibaldi, Michele Romano, Mario R. The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title | The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title_full | The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title_fullStr | The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title_full_unstemmed | The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title_short | The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes |
title_sort | short-term results of autologous platelet-rich plasma as an adjuvant to re-intervention in the treatment of refractory full-thickness macular holes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004127/ https://www.ncbi.nlm.nih.gov/pubmed/36902837 http://dx.doi.org/10.3390/jcm12052050 |
work_keys_str_mv | AT buzzimatilde theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT parisiguglielmo theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT marolopaola theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT gelorminifrancesco theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT ferraramariantonia theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT raimondiraffaele theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT allegrinidavide theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT rossitommaso theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT reibaldimichele theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT romanomarior theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT buzzimatilde shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT parisiguglielmo shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT marolopaola shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT gelorminifrancesco shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT ferraramariantonia shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT raimondiraffaele shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT allegrinidavide shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT rossitommaso shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT reibaldimichele shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes AT romanomarior shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes |